Skip to main content
      RT @RHEUMarampa: ProDERM study:10% IVIG is effective and safe in pts with DM. First large PBO-controlled, randomized ph

      sheila RHEUMarampa

      4 years ago
      ProDERM study:10% IVIG is effective and safe in pts with DM. First large PBO-controlled, randomized ph 3 trial. @RheumNow #ACR20 abs0995 #ACRbest https://t.co/aJyASaAMlJ
      RT @ejdein1: Dr. Burmester on serendipity in the development of rheumatologic meds. As we study #COVID19, we need to kee

      Eric Dein ejdein1

      4 years ago
      Dr. Burmester on serendipity in the development of rheumatologic meds. As we study #COVID19, we need to keep our minds open that we don't always find what we want, but we can always learn something to bring us ahead. #ACR20 @Rheumnow. https://t.co/s5WZEjrbnk
      RT @uptoTate: Australian study looking at clinical outcomes following in-class switching vs switching MOA. Rapid effect

      Dr. Rachel Tate uptoTate

      4 years ago
      Australian study looking at clinical outcomes following in-class switching vs switching MOA. Rapid effect of IL-17i and JAKi with PsA rated highly. This study highlights ever-growing need for precision medicine based on domain. #ABS09003 #ACR20 @RheumNow https://t.co/7qKH6aw6f0
      RT @DrMiniDey: #HCQ assoc. w/ ↓platelet activity & ↑vascular health in #SLE:
      - 132 patients, 108 on HCQ
      - Ex-viv

      Mrinalini Dey DrMiniDey

      4 years ago
      #HCQ assoc. w/ ↓platelet activity & ↑vascular health in #SLE: - 132 patients, 108 on HCQ - Ex-vivo expts show ↓platelet aggregation & downregulation of platelet functional pathways - HCQ may improve vascular health in SLE Abs#0870 #ACR20 @RheumNow https://t.co/ST9n2HGyhM
      RT @uptoTate: CZP tx in axSpA pts showed significant reduction of 82% in the AAU flare rate and MSK symptoms over 96 wee

      Dr. Rachel Tate uptoTate

      4 years ago
      CZP tx in axSpA pts showed significant reduction of 82% in the AAU flare rate and MSK symptoms over 96 week C-VIEW trial. #ABS0881 #ACR20 @RheumNow https://t.co/bNFHXbKEuF https://t.co/3Z232vKGPC
      RT @RHEUMarampa: In this study of RA pts w/ b/tsDMARDs tx, continuous decrease in RF titers was assoc'd w/ radiographic

      sheila RHEUMarampa

      4 years ago
      In this study of RA pts w/ b/tsDMARDs tx, continuous decrease in RF titers was assoc'd w/ radiographic remission. Other factors were dse duration<5yrs, pred<5mg/d & time-integrated DAS28ESR. @RheumNow #ACR20 abs0754 https://t.co/u0pgAsK4UX
      RT @MeralElRamahiMD: Important to tailor our approach based on patient preferences, and this abstract shows that geriatr

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years ago
      Important to tailor our approach based on patient preferences, and this abstract shows that geriatric patients have different desires for care! #ACR20 @RheumNow https://t.co/pY3VTeURSS
      RT @Janetbirdope: Most ignore pharmacists annoying faxes re safety of QT interval with #hydroxycholoroquine likely the r

      Janet Pope Janetbirdope

      4 years ago
      Most ignore pharmacists annoying faxes re safety of QT interval with #hydroxycholoroquine likely the right thing to do! @RheumNow #ACR2020 @CRASCRRheum abstr#431. https://t.co/pXBIDOV2MP
      RT @RHEUMarampa: SKIPPAIN trial: SEC showed rapid and significant improvement of spinal pain (primary endpt) and ⬇ dis

      sheila RHEUMarampa

      4 years ago
      SKIPPAIN trial: SEC showed rapid and significant improvement of spinal pain (primary endpt) and ⬇ disease activity in axSpA @RheumNow #ACR20 abs0899 #ACRbest https://t.co/fKSEjwd6i9
      RT @RHEUMarampa: Anti-PAD Abs seen in 1/3 of pts at-risk for RA and 1/3 of pts w/ CSA.
      Implications? Possible predictiv

      sheila RHEUMarampa

      4 years ago
      Anti-PAD Abs seen in 1/3 of pts at-risk for RA and 1/3 of pts w/ CSA. Implications? Possible predictive value of anti-PAD Abs in RA dse progression? @RheumNow #ACR20 abs0761 #ACRbest https://t.co/VpkjwU2YZm
      RT @DrMiniDey: Data from MUSE &amp; TULIP trials of #anifrolumab in #SLE show increased risk of #herpeszoster when compa

      Mrinalini Dey DrMiniDey

      4 years ago
      Data from MUSE & TULIP trials of #anifrolumab in #SLE show increased risk of #herpeszoster when compared to placebo. Most HZ events mild-moderate, cutaneous and resolved without discontinuation of drug. #RheumTwitter #lupus Abs#0849 #ACR20 @RheumNow https://t.co/8a6OcZmOso
      RT @lexmeara: The development of biologics started with diphtheria- history of Medicine! Look how far we have come now p

      alexa meara lexmeara

      4 years ago
      The development of biologics started with diphtheria- history of Medicine! Look how far we have come now prescribing over 50 different types of biologics! @RheumNow #acr20 https://t.co/XbygK5g7ON
      RT @uptoTate: BKZ tx improved BASDAI total and single question scores related to fatigue and neck, back and hip pain in

      Dr. Rachel Tate uptoTate

      4 years ago
      BKZ tx improved BASDAI total and single question scores related to fatigue and neck, back and hip pain in pts with PsA. #ABS0906 #ACR20 @RheumNow https://t.co/GzpJfkwvL5 https://t.co/KnJAqAKlqq
      RT @Janetbirdope: Do pts with RA take their meds &amp; can adherence intervention work? Yes &amp; No. Pts starting new b

      Janet Pope Janetbirdope

      4 years ago
      Do pts with RA take their meds & can adherence intervention work? Yes & No. Pts starting new bDMARD RCT of electronic monitoring feedback vs usual care, adherence>80%. Neg RCT Maybe chronic users with poor adherence is group to study abstr#0799 #ACR2020 @RheumNow https://t.co/FyWoBjYnvs
      RT @DrMiniDey: Valerio et al find 40% of 294 patients w/ #rheumaticdisease refuse or are uncertain about getting inactiv

      Mrinalini Dey DrMiniDey

      4 years ago
      Valerio et al find 40% of 294 patients w/ #rheumaticdisease refuse or are uncertain about getting inactivated #influenza #vaccine. Key determinants of #vaccinehesitancy found to be concerns about adverse events, safety & efficacy. Abs#0632 #ACR20 @RheumNow https://t.co/f34DAc5WiN